{"schema_version":"secwatch.filing_event.v1","accession":"0001785530-26-000005","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.171292+00:00","generated_at":"2026-05-15T08:40:17.517477+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Werewolf Therapeutics announces strategic alternatives review; Q4 2025 net loss $8.4M","bullets":["Engaged Piper Sandler as exclusive financial advisor to explore strategic alternatives including sale, merger, or asset sale.","Cash and equivalents of $57.1M as of Dec 31, 2025; expected to fund operations into Q4 2026.","Q4 2025 net loss $8.4M vs $20.4M in Q4 2024; R&D expenses $6.9M vs $15.7M.","Full year 2025 net loss $60.8M vs $70.5M; R&D expenses $44.8M vs $56.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0001785530-26-000005","json":"https://secwatch.observer/filing/0001785530-26-000005.json","markdown":"https://secwatch.observer/filing/0001785530-26-000005.md","text":"https://secwatch.observer/filing/0001785530-26-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000178553026000005/0001785530-26-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000178553026000005/howl-20260327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:40:17.517477+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34a156d59d5f092c5b963c39ef4e16742e742213","claim":"Werewolf Therapeutics, Inc. reported full year ended December 31, 2025 results: net income Net loss was $60.8 million.","evidence_excerpt":"Net loss was $60.8 million for the full year 2025","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785530/000178553026000005/0001785530-26-000005-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2025"},{"label":"Net income","value":"Net loss was $60.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a8449f28991699811972d269959a41df15494b19","claim":"Werewolf Therapeutics, Inc. reported quarter ended December 31, 2025 results: net income Net loss was $8.4 million.","evidence_excerpt":"Net loss was $8.4 million for the fourth quarter of 2025","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785530/000178553026000005/0001785530-26-000005-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended December 31, 2025"},{"label":"Net income","value":"Net loss was $8.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}